Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €88.56 EUR
Change Today -0.36 / -0.40%
Volume 106.8K
BIM On Other Exchanges
BIM is not on other exchanges.
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/15 - €98.89
52 Week Low
04/14/14 - €76.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was formerly known as B-D Mérieux and changed its name to bioMérieux SA. The company was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €544.9K
Compensation as of Fiscal Year 2013.

biomerieux (BIM) Key Developments

bioMérieux SA to Recommend Dividend for the Year 2014, Payable on June 9, 2015; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Capital Expenditure Guidance for the Year of 2015

The board of directors of bioMérieux SA will recommend that shareholders at the Annual Meeting on May 28, 2015 approve a dividend of EUR 1 per share, unchanged from the dividend paid in 2014. This would represent a total payout of EUR 39.5 million, to be paid on June 9, 2015. The company reported audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported sales of EUR 1,698.4 million compared to EUR 1,587.9 million a year ago. Operating income before non-recurring items was EUR 202.9 million compared to EUR 260.5 million a year ago. Operating income was EUR 203.6 million compared to EUR 257.5 million a year ago. Net income of consolidated companies was EUR 135.5 million or EUR 3.42 per basic and diluted share compared to EUR 164.7 million or EUR 4.16 per basic and diluted share a year ago. EBITDA was EUR 332.2 million compared to EUR 353.3 million a year ago. Net cash flow from operations was EUR 298.3 million compared to EUR 240.5 million a year ago. Purchase of property, plant and equipment was EUR 158.1 million compared to EUR 131.1 million a year ago. Free cash flow was EUR 158 million compared to EUR 111 million a year ago. Net debt amounted to EUR 249 million at December 31, 2014, compared with EUR 25 million in net cash a year earlier. The company expects to drive sales growth of between 3% and 5% in 2014, at constant exchange rates and scope of consolidation. The company expected to generate around EUR 60 million in sales in 2014, while its contribution to the growth in consolidated sales will be reported in "changes in the scope of consolidation" for the year. Contributive operating income before non-recurring items of between EUR 220 million and EUR 245 million, after recognition of company’s recurring operations, the investments required at the Durham site and the currency effect (at least an estimated EUR 25 million on the basis of current exchange rates). The company has set an organic growth objective of between 4.5% and 6.5% for the year, at constant exchange rates and scope of consolidation. The company is aiming to increase contributive operating income before non-recurring items to between EUR 240 million and EUR 265 million in 2015, at current exchange rates. This objective reflects the selling costs that will be invested to ensure FilmArray®'s success and the operating expenses that will be incurred to strengthen the operating organization in the Asia-Pacific and to anchor the company's sustained development in the region. This objective also includes the priority projects that will be led by the company in 2015 to enhance its operating performance, in particular by revamping the supply chain and improving customer service, deploying new sales performance management applications and optimizing the management of R&D programs. In addition, using its structural capacity for strong cash generation, the company will increase its industrial capital expenditure potentially to around EUR 200 million.

bioMerieux and Astute Medical, Inc. Signs Agreement to Develop Test for Assessment of AKI

bioMerieux and Astute Medical, Inc. have signed a global, semi-exclusive agreement to develop a test for the early risk assessment of acute kidney injury, or AKI. This innovative test, known as the NephroCheck Test, detects the presence of two biomarkers: TIMP-2 (Tissue Inhibitor Metalloproteinases-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7). Through this worldwide agreement, Astute Medical grants bioMerieux a license to develop, produce and market the NephroCheck Test for use on its immunoassay system range VIDAS, miniVIDAS and VIDAS 3. Deployment of the NephroCheck Test for the VIDAS platform will benefit from the VIDAS installed base of about 29,000 systems and from complementary large product offering dedicated to diagnosis of severe bacterial infections, in particular with VIDAS B.R.A.H.M.S. PCT. With this new assay, bioMerieux will reinforce its leading position in the risk assessment and diagnosis of patients in an emergency situation, including those with sepsis and high risk of severe medical complications. To validate TIMP-2 and IGFBP-7 as biomarkers for AKI risk assessment, Astute analyzed the biomarkers in two rigorous company-sponsored, multicenter, observational clinical studies. In these studies, the NephroCheck Test identified the majority of patients manifesting moderate or severe AKI within 12 hours of assessment.

bioMérieux SA to Report Fiscal Year 2014 Results on Jan 22, 2015

bioMérieux SA announced that they will report fiscal year 2014 results Pre-Market on Jan 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €88.56 EUR -0.36

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $48.18 USD +1.51
Bio-Rad Laboratories Inc $134.95 USD +0.06
Bruker Corp $18.30 USD +0.05
Cepheid $54.14 USD +0.93
QIAGEN NV €23.15 EUR +0.378
View Industry Companies

Industry Analysis


Industry Average

Valuation BIM Industry Range
Price/Earnings 23.4x
Price/Sales 1.8x
Price/Book 2.3x
Price/Cash Flow 23.4x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at